Earnings Estimate Revisions for Actinium This cancer drug developer is expected to earn -$1.38 per share for the fiscal year ending December 2024, which represents a year-over-year change of 24.6%.

(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM) Tuesday has launched a clinical program evaluating Actimab-A in combination with the PD-1 inhibitors pembrolizumab - KEYTRUDA and nivolumab OPDIVO.

I n a challenging year for Actinium Pharmaceuticals (NYSE:ATNM), the company's stock has touched a 52-week low, trading at $1.1, marking an 80% decline from its 52-week high of $10.24. According ...

Actinium combines the precise targeting ability of monoclonal antibodies with the proven cancer-fighting power of radiation to develop innovative therapies for patients with cancers lacking ...

- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA ® or OPDIVO ® can result in improved patient outcomes - MDSCs – Myeloid Derived Suppressor Cells in ...

Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radioligand ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports.

Actinium Pharmaceuticals (ATNM) has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center to expand Actimab-A’s mutation agnostic mechanism of action. The ...

Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced it has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC ...

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or ...